KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study.

Hidenori Arai, Shizuya Yamashita, Eiichi Araki, Koutaro Yokote, Ryohei Tanigawa, Ayumi Saito, Daisuke Furukawa, Hideki Suganami, Shun Ishibashi

J Atheroscler Thromb 32(8) 1006-1026

PMID39924184
PMCIDPMC12328711
DOI10.5551/jat.65350
发表日期2025-02-09
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig.1. Disposition of patients:AI 判定为 flow diagram;Fig.2. Change in fasting serum TG levels:AI 判定为 other。
摘要

摘要

AIMS: Long-term safety and efficacy of pemafibrate once-daily extended-release (XR) tablets, taken in morning or evening, were evaluated in dyslipidemic patients with high triglycerides (TG). METHODS: In this multicenter, randomized, open-label, parallel-group, phase 3 long-term study, dyslipidemic patients with high TG were randomly assigned to morning or evening administration of XR for 52 weeks. The dose was started at 0.2 mg/day and increased to 0.4 mg/day for patients having fasting serum TG ≥ 150mg/dL during treatment. The primary efficacy endpoint was percent change in fasting serum TG. RESULTS: The study enrolled 121 patients, assigning 61 to morning and 60 to evening administration. The study population included 71.1% males. Mean age was 58.5±11.1 (mean±SD) years, body mass index 27.7±4.3 kg/m2, and fasting TG 264.0±109.2 mg/dL. Fasting serum TG decreased significantly from baseline to 52 weeks among patients overall and in the morning and evening groups (-45.7%, -44.8%, and -46.6%, respectively, p<0.001 vs. baseline). The difference in least-squares mean between the morning and evening groups was 3.0%, not statistically significant. The dose was increased in 82 patients (44 morning and 38 evening), with 57.3% (95%CI 45.9, 68.2) achieving fasting serum TG <150 mg/dL. Adverse events occurred in 83.5% and adverse drug reactions in 19.0% but with no notable safety problems. CONCLUSIONS: Long-term, once-daily administration of XR was effective and safe in dyslipidemic patients with high TG. XR provided favorable TG-lowering effects regardless of morning or evening administration, and the XR dose increase proved effective in patients having initially inadequate response.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig.1. Disposition of patientsFig.1. Disposition of patients § Colon cancer ( n = 1); arrhythmia ( n = 1). † Myocardial infarction ( n = 1); myalgia ( n = 1); aortic valve stenosis, asthenia, myalgia, feeling abnormal ( n = 1); eczema ( n = 1); blood creatine phosphokinase increased ( n = 1). TG, triglycerides.
非 KM Figure
Fig.2. Change in fasting serum TG levelsFig.2. Change in fasting serum TG levels (A) Mean percent change in fasting serum TG at 52 weeks (overall population, morning group, evening group) Basic statistics. Data are presented as mean ±95%CI for basic statistics. *** p <0.001 vs. baseline. (B) Changes in actual measured values for fasting serum TG (overall population, morning group, evening group) Data are presented as mean±standard deviation. *** p <0.001 vs. baseline by one-sample t -test for each group. CI, confidence interval; LS, least squares; TG, triglycerides.
非 KM Figure